Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitravatinib plus Tislelizumab as Adjuvant Treatment in HCC
NCT05564338Phase 3Withdrawn
- Sponsor
- BeiGene
- Start
- Jun 2023
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies, Bispecific Antibodies, Small Molecules
01
Overview
A Phase 3 trial of sitravatinib, tislelizumab in hepatocellular carcinoma (HCC), sponsored by BeiGene. Planned start Jun 2023; status: withdrawn.
02
Drugs
sitravatinibtislelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05564338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05564338.